Table of Contents
ISRN Hematology
Volume 2012 (2012), Article ID 139862, 8 pages
http://dx.doi.org/10.5402/2012/139862
Research Article

Comparative Effects of Three Iron Chelation Therapies on the Quality of Life of Greek Patients with Homozygous Transfusion-Dependent Beta-Thalassemia

1Department of Pharmacy, General Hospital of Agrinio, Kokkali Street, 30100 Agrinio, Greece
2Thalassemia and Hemoglobinopathies Centre, Hematology Division, University Hospital of Patras, Patras, Greece
3Laboratory of Pharmaceutical Chemistry, Department of Pharmacy, University of Patras, Patras, Greece

Received 23 October 2012; Accepted 8 November 2012

Academic Editors: E. Balleari, E. Cobos, and H. Knecht

Copyright © 2012 Vasilis Goulas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Hardison, D. H. K. Chui, B. Giardine et al., “HbVar. A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server,” Human Mutation, vol. 19, no. 3, pp. 225–233, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. G. P. Patrinos, B. Giardine, C. Riemer et al., “Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for populations and sequence variation studies,” Nucleic Acids Research, vol. 32, pp. D537–D41, 2004. View at Google Scholar · View at Scopus
  3. A. Papachatzopoulou, A. Kourakli, E. F. Stavrou et al., “Region-specific genetic heterogeneity of HBB mutation distribution in South-Western Greece,” Hemoglobin, vol. 34, no. 4, pp. 333–342, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. G. P. Patrinos, S. Van Baal, M. B. Petersen, and M. N. Papadakis, “Hellenic national mutation database: a prototype database for mutations leading to inherited disorders in the hellenic population,” Human Mutation, vol. 25, no. 4, pp. 327–333, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Modell, M. Khan, and M. Darlison, “Survival in β-thalassaemia major in the UK: data from the UK thalassaesnia register,” The Lancet, vol. 355, no. 9220, pp. 2051–2052, 2000. View at Google Scholar · View at Scopus
  6. C. Borgna-Pignatti, S. Rugolotto, P. De Stefano et al., “Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine,” Haematologica, vol. 89, no. 10, pp. 1187–1193, 2004. View at Google Scholar · View at Scopus
  7. R. Monastero, G. Monastero, C. Ciaccio, A. Padovani, and R. Camarda, “Cognitive deficits in beta-thalassemia major,” Acta Neurologica Scandinavica, vol. 102, no. 3, pp. 162–168, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Economou, D. I. Zafeiriou, E. Kontopoulos et al., “Neurophysiologic and intellectual evaluation of beta-thalassemia patients,” Brain and Development, vol. 28, no. 1, pp. 14–18, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. D. I. Zafeiriou, M. Economou, and M. Athanasiou-Metaxa, “Neurological complications in β-thalassemia,” Brain and Development, vol. 28, no. 8, pp. 477–481, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. E. Ware, M. Kosinski, and S. D. Keller, SF-36 Physical and Mental Health Summary Scales: A User's Manual, The Health Institute, Boston, Mass, USA, 1994.
  11. B. S. Wallston and K. A. Wallston, “Health locus of control,” in Research With the Locus of Control Construct, H. Lefcourt, Ed., vol. 1, Academic Press, New York, NY, USA, 1981. View at Google Scholar
  12. K. M. Musallam, B. Khoury, R. Abi-Habib et al., “Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights,” European Journal of Haematology, vol. 87, no. 1, pp. 73–79, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Politis, A. Di Palma, M. Fisfis et al., “Social integration of the older thalassaemic patient,” Archives of Disease in Childhood, vol. 65, no. 9, pp. 984–986, 1990. View at Google Scholar · View at Scopus
  14. R. Origa, P. Bina, A. Agus et al., “Combined therapy with deferiprone and desferrioxamine in thalassemia major,” Haematologica, vol. 90, no. 10, pp. 1309–1314, 2005. View at Google Scholar · View at Scopus
  15. R. A. Risdon, M. Barry, and D. M. Flynn, “Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia,” Journal of Pathology, vol. 116, no. 2, pp. 83–95, 1975. View at Google Scholar · View at Scopus
  16. G. Jean, S. Terzoli, and R. Mauri, “Cirrhosis associated with multiple transfusions in thalassaemia,” Archives of Disease in Childhood, vol. 59, no. 1, pp. 67–70, 1984. View at Google Scholar · View at Scopus
  17. A. Pathare, A. Taher, and S. Daar, “Deferasirox (Exjade) significantly improves cardiac T2 in heavily iron-overloaded patients with beta-thalassemia major,” Annals of Hematology, vol. 89, no. 4, pp. 405–409, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Pepe, A. Meloni, M. Capra et al., “Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging,” Haematologica, vol. 96, no. 1, pp. 41–47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. D. Cappellini, M. Bejaoui, L. Agaoglu et al., “Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia,” Clinical Therapeutics, vol. 29, no. 5, pp. 909–917, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Taher, A. Al Jefri, M. S. Elalfy et al., “Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: results from the ESCALATOR trial,” Acta Haematologica, vol. 123, no. 4, pp. 220–225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Abetz, J. F. Baladi, P. Jones, and D. Rofail, “The impact of iron overload and its treatment on quality of life: results from a literature review,” Health and Quality of Life Outcomes, vol. 4, p. 73, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. Z. Pakbaz, M. Treadwell, R. Yamashita et al., “Quality of life in patients with thalassemia intermedia compared to thalassemia major,” Annals of the New York Academy of Sciences, vol. 1054, pp. 457–461, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Ismail, M. J. Campbell, H. M. Ibrahim, and G. L. Jones, “Health related quality of life in Malaysian children with thalassaemia,” Health and Quality of Life Outcomes, vol. 4, p. 39, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. J. J. Caro, A. Ward, T. C. Green et al., “Impact of thalassemia major on patients and their families,” Acta Haematologica, vol. 107, no. 3, pp. 150–157, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Scalone, L. G. Mantovani, M. Krol et al., “Costs, quality of life, treatment satisfaction and compliance in patients with β-thalassemia major undergoing iron chelation therapy: the ITHACA study,” Current Medical Research and Opinion, vol. 24, no. 7, pp. 1905–1917, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Sobota, R. Yamashita, Y. Xu et al., “Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms,” American Journal of Hematology, vol. 86, no. 1, pp. 92–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Azarkeivan, B. Hajibeigi, S. M. Alavian, M. M. Lankarani, and S. Assari, “Associates of poor physical and mental health-related quality of life in beta thalassemia-major/intermedia,” Journal of Research in Medical Sciences, vol. 14, no. 6, pp. 349–355, 2009. View at Google Scholar · View at Scopus